The complex role of AR signaling after cytotoxic insult - Implications for cell cycle based chemotherapeutics

被引:25
作者
Comstock, Clay E. S.
Knudsen, Karen E.
机构
[1] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH USA
[2] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH USA
[3] Univ Cincinnati, Coll Med, Barrett Canc Ctr, Cincinnati, OH USA
关键词
prostate cancer; androgen receptor; pre-clinical; taxane; docetaxel; flavopiridol;
D O I
10.4161/cc.6.11.4353
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Prostatic adenocarcinomas are dependent on androgen receptor (AR) signaling for growth and progression, in part through the ability of AR to induce G(1)-S phase cell cycle transition. Hormonal therapies that inhibit AR activity are the first line of intervention for disseminated disease, and are initially quite effective; however, recurrent, incurable tumors ultimately arise with restored AR function. Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival. Recent studies have challenged the utility of manipulating AR activity to enhance cell death in combination with genotoxic insult. Herein, the role of AR in controlling cell cycle progres sion and paradoxical roles of AR in survival signals are considered, as are the potential implications of these findings for chemotherapeutic response. Although there is much to be resolved, the present data suggest that knowledge of AR action in promoting cellular proliferation can be utilized for the design of coordinate strategies that maximize cell death in response to cytotoxic chemotherapeutics.
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 93 条
[51]   Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells [J].
Lim, JTE ;
Mansukhani, M ;
Weinstein, IB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (14) :5156-5161
[52]   Androgen and its receptor promote Bax-mediated apoptosis [J].
Lin, YT ;
Kokontis, J ;
Tang, FM ;
Godfrey, B ;
Liao, SS ;
Lin, AN ;
Chen, YT ;
Xiang, JL .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (05) :1908-1916
[53]   Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells [J].
Litvinov, Ivan V. ;
Vander Griend, Donald J. ;
Antony, Lizamma ;
Dalrymple, Susan ;
De Marzo, Angelo M. ;
Drake, Charles G. ;
Isaacs, John T. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (41) :15085-15090
[54]   A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer [J].
Liu, G ;
Gandara, DR ;
Lara, PN ;
Raghavan, D ;
Doroshow, JH ;
Twardowski, P ;
Kantoff, P ;
Oh, W ;
Kim, KM ;
Wilding, G .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :924-928
[55]   Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents [J].
Lu, K ;
Shih, C ;
Teicher, BA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (04) :293-304
[56]   The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells [J].
Lu, LF ;
Schulz, H ;
Wolf, DA .
BMC CELL BIOLOGY, 2002, 3 (1)
[57]   Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter [J].
Lu, S ;
Liu, M ;
Epner, DE ;
Tsai, SY ;
Tsai, MJ .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (03) :376-384
[58]  
Lü X, 2004, MOL CANCER THER, V3, P861
[59]   Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner [J].
Mantoni, T. S. ;
Reid, G. ;
Garrett, M. D. .
ONCOGENE, 2006, 25 (22) :3139-3149
[60]   Loss of androgen receptor transcriptional activity at the G1/S transition [J].
Martinez, ED ;
Danielsen, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (33) :29719-29729